20 Years into the Gambia Hepatitis Intervention Study: Assessment of Initial Hypotheses and Prospects for Evaluation of Protective Effectiveness Against Liver Cancer
20 Years into the Gambia Hepatitis Intervention Study: Assessment of Initial Hypotheses and Prospects for Evaluation of Protective Effectiveness Against Liver Cancer
复制标题
DOI：
10.1158/1055-9965.epi-08-0303
复制
发表时间：
2008-11-01
影响因子：
3.8
通讯作者：
Hainaut, Pierre
中科院分区：
文献类型：
--
作者：
Viviani, Simonetta;Carrieri, Patrizia;Hainaut, Pierre
原发性肝细胞癌是冈比亚最常见的癌症。冈比亚肝炎干预研究（GHIS）成立于1986年，旨在评估婴儿B型肝炎免疫接种在预防慢性肝病，特别是成年后肝细胞癌和肝硬化方面的保护效果。这个程序是基于一系列假设而设计的。在这里，我们使用自1986年以来开发的观察和流行病学研究的数据来检验这些假设的有效性。我们发现：（a）B型肝炎疫苗覆盖率比最初假设的高15%，（B）对B型肝炎病毒（HBV）感染的保护作用不依赖于接受疫苗剂量的数量，（C）围产期HBV感染的重要性可以忽略不计，（d）年龄时HBV可归因于肝细胞癌的风险
Primary hepatocellular carcinoma is the commonest cancer in The Gambia. The Gambia Hepatitis Intervention Study (GHIS) was established in 1986 to evaluate the protective effectiveness of infant hepatitis B immunization in the prevention of chronic liver disease, particularly, hepatocellular carcinoma and cirrhosis later in adult life. This program was designed based on a series of assumptions. Here, we used data from observational and epidemiologic studies developed since 1986 to examine the validity of these assumptions. We found that (a) hepatitis B vaccine coverage was 15% more than originally assumed, (b) protection against hepatitis B virus (HBV) infection was not dependent on the number of vaccine doses received, (C) perinatal infection with HBV was of negligible importance, and (d) the HBV attributable risk of hepatocellular carcinoma at age